Ask AI

Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC

This educational program aims to enhance the knowledge, competence, and confidence of healthcare professionals in assessing and managing high-risk HR+/HER2- EBC by focusing on ways to effectively communicate risk assessment to patients and measures to implement optimal therapeutic strategies to reduce recurrence risk and optimize treatment outcomes.

Share

Program Content

Activities

Role of CDK4/6 Inhibitors in HR+/HER2- EBC
Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2025

Expires: January 23, 2026

Adjuvant Treatment of HR Positive HER2 Negative EBC
Integrating the Evidence on Adjuvant Therapy for High-risk HR-Positive/HER2-Negative Early Breast Cancer
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 07, 2025

Expires: February 06, 2026

Mitigating Recurrence Risk in HRpos HER2neg EBC
Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 24, 2026

Expires: April 23, 2027

Activities

QI Initiative
Mitigating Recurrence Risk: A Multisite QI Initiative to Improve Clinical Outcomes and Management in Patients With High-Risk HR+/HER2- EBC
Video
Congratulations: You achieved a completion on 04/09/2022

Released: May 21, 2026

Expires: May 20, 2027

Activities

Role of CDK4/6 Inhibitors in HR+/HER2- EBC
Risk Factors for Recurrence, Molecular Testing, and Treatment of Patients With HR-Positive/HER2-Negative EBC
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2025

Expires: January 23, 2026

Adjuvant Treatment of HR Positive HER2 Negative EBC
Integrating the Evidence on Adjuvant Therapy for High-risk HR-Positive/HER2-Negative Early Breast Cancer
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 05, 2025

Expires: February 04, 2026

Activities

Discussion about High-Risk HR+/HER2- EBC
Discussing Newer Treatment Options and What to Expect With Patients With High-Risk HR+/HER2- Early Breast Cancer
Video
Congratulations: You achieved a completion on 04/09/2022

Released: October 29, 2024

Expires: October 28, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education, in partnership with Q Synthesis and The American Society of Breast Surgeons Foundation.

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Q Synthesis LLC

ProCE Banner

The American Society of Breast Surgeons Foundation

ProCE Banner